NCT05271630: Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Transplant

NCT05271630: Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant

Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant

The purpose of the study is to determine outcomes for Multiple Myeloma patients on maintenance single agent vs. doublet (IMiD + PI) combination chemotherapy post Autologous Stem Cell Transplant (ASCT).

Minimal Residual Disease (MRD) testing by Clonoseq will be performed in the peripheral blood of the patients at the same time points that MRD testing will be done in the bone marrow in addition to at 6 and 18 months.

Sponsor:

H. Lee Moffitt Cancer Center and Research Institute

Collaborator:

Adaptive Biotechnologies

---

ClinicalTrials.gov Identifier: NCT05172596

Official Title: Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant

First Posted : March 9, 2022

Click here to see details on ClinicalTrials.gov

---

Other: Autologous Stem Cell Transplant

Drug: Immunomodulatory Agent

Drug: Proteasome Inhibitor

---

Location:

United States, Florida

Moffitt Cancer Center

Tampa, Florida, United States, 33612